Skip to content
See the World Through ScienceA project of ALLATRA

FDA Approves a Pill Combination for Breast Cancer That Kept Growing on Hormone Therapy

Science

Republish this story

Our work is licensed under Creative Commons BY-NC 4.0. You may republish this piece for free — with credit to ALLATRA Media and a link to the original, unedited beyond length trims, and not for commercial use.

Read the full license

Fluorescence microscopy image of a rounded cluster of breast tumor cells grown in three dimensions, with green cytoplasm, blue nuclei and one red patch of cells.
Cells within one breast tumor differ from each other, labeled here by fluorescence microscopy (illustrative)."Heterogeneous breast tumor in 3D" by Sshah74, via Wikimedia Commons, CC BY 4.0

On Nov. 16, 2026, the U.S. Food and Drug Administration approved giredestrant, an oral estrogen receptor blocker that Genentech will sell as Wilserdly, for use with everolimus in adults whose advanced breast cancer carries a mutation in the ESR1 gene. The agency also authorized a test, FoundationOne Liquid CDx, to identify those patients by reading tumor DNA that circulates in the blood.

The combination is cleared for breast cancer that grows in response to estrogen and is not driven by the HER2 protein, once the disease has spread or advanced locally. The FDA's indication covers patients whose cancer came back during or after hormone-based treatment given after surgery, and patients whose cancer kept growing on at least one hormone-based regimen after it had spread.

The approval notification rests on evERA Breast Cancer, an open-label trial that randomly assigned 373 adults, 207 of whom had tumors carrying the mutation. In that group, the agency reports a median of 10 months before the disease worsened among patients taking giredestrant with everolimus, against 5.5 months among those given a hormone drug of the doctor's choosing. The choices were exemestane, fulvestrant or tamoxifen, each taken with everolimus. Tumors shrank in roughly twice as many patients on giredestrant. Survival data were immature when that analysis was done, the agency adds, so the trial does not show whether patients live longer.

The FDA lists mouth inflammation, rash, fatigue, diarrhea, muscle and joint pain, lung inflammation and nausea as the side effects seen in at least a fifth of patients on the combination. The prescribing information carries warnings for a slow heartbeat and for harm to a fetus.

The review ran under Project Orbis, a program through which regulators in several countries examine a cancer drug at the same time. The FDA worked on it with Health Canada and Israel's Ministry of Health, and says the applications may still be under review at those agencies. Full prescribing information for Wilserdly will be posted on Drugs@FDA.

Sources

Medical Disclaimer: This content is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, concern, symptom, or treatment decision.

Spot an error?

Spot an error?

Report an error

Spotted a mistake on this page? Tell us what's wrong and our editors will take a look.

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We correct mistakes openly. Select any text to flag it. Fixes are logged under our Corrections Policy.

Report an error

Reporting on

FDA Approves a Pill Combination for Breast Cancer That Kept Growing on Hormone Therapy

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We read every report. Corrections are logged publicly.